Decades old tuberculosis vaccine directly injected into veins could turbocharge protection, monkey study finds
A century-old tuberculosis (TB) vaccine may be a candidate for a facelift after animal study data suggest administering it intravenously can augment its efficacy.
The vaccine developed to combat TB — the deadliest global infection — is based on a live strain of the related pathogen Mycobacterium bovis, which was attenuated between 1908 and 1921. The strain, known as bacille Calmette–Guérin (BCG), has since been administered to more than one billion people, according to the WHO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.